Trillium Asset Management LLC Invests $12.96 Million in Boston Scientific Corporation $BSX

Key Points

• Trillium Asset Management acquired 303,755 Boston Scientific shares worth approximately $12.96 million, while institutional investors overall own 89.07% of the company.
• Analysts maintain a generally positive outlook, with 24 Buy, five Hold and two Sell ratings; the consensus is Moderate Buy with an average price target of $71.62, despite several recent target reductions.
• Boston Scientific exceeded quarterly expectations with $0.86 EPS and $5.44 billion in revenue, up 7.5% year over year. The company also authorized a $5 billion share repurchase plan, and insiders purchased roughly $9.4 million of stock over the past three months.

Trillium Asset Management LLC acquired a new stake in Boston Scientific Corporation (NYSE:BSX - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 303,755 shares of the medical equipment provider's stock, valued at approximately $12,964,000.

A number of other institutional investors also recently modified their holdings of the stock. FWL Investment Management LLC bought a new stake in Boston Scientific in the second quarter valued at $26,000. Swiss RE Ltd. acquired a new stake in shares of Boston Scientific in the 4th quarter valued at about $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific in the 4th quarter valued at about $26,000. Sfam LLC bought a new stake in Boston Scientific in the 4th quarter valued at about $29,000. Finally, Cresta Advisors Ltd. acquired a new position in Boston Scientific during the 4th quarter worth approximately $33,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Royal Bank Of Canada cut their price target on Boston Scientific from $85.00 to $70.00 and set an "outperform" rating on the stock in a report on Thursday, July 30th. Citigroup lowered their target price on Boston Scientific from $70.00 to $61.00 and set a "buy" rating on the stock in a research report on Thursday, July 30th. Mizuho cut their target price on Boston Scientific from $90.00 to $70.00 and set an "outperform" rating on the stock in a report on Wednesday, July 15th. Raymond James Financial reissued an "outperform" rating and issued a $57.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Finally, Argus restated a "hold" rating on shares of Boston Scientific in a report on Friday, July 31st. Twenty-four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $71.62.

Insiders Place Their Bets

In other news, Director David C. Habiger acquired 2,100 shares of the firm's stock in a transaction on Wednesday, August 5th. The stock was purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Edward J. Ludwig bought 5,000 shares of the company's stock in a transaction on Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the transaction, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 194,522 shares of company stock valued at $9,385,210 in the last three months. 0.34% of the stock is currently owned by insiders.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $49.47 on Friday. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The business has a 50 day moving average price of $46.26 and a 200-day moving average price of $57.91. The company has a market cap of $71.69 billion, a PE ratio of 20.03, a price-to-earnings-growth ratio of 1.13 and a beta of 0.56.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to analysts' expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.Boston Scientific's quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a stock repurchase plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback plans are often an indication that the company's board of directors believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source